Galena Biopharma to Report Third Quarter Financial Results and Provide Business Update on Monday, November 9, 2015
26 oct. 2015 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address...
Galena Biopharma to Present GALE-302 Preliminary Immunological Data Optimizing GALE-301, and the Phase 2 NeuVax(TM) Data Impact on Cancer Survivorship at Two Upcoming Medical Conferences
22 oct. 2015 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Ductal Carcinoma in Situ Patients
30 sept. 2015 07h05 HE
|
Galena Biopharma, Inc.
PORTLAND, Ore., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
Galena Biopharma Presents Positive GALE-301 Phase 2a Clinical Trial Data at the European Cancer Congress 2015
28 sept. 2015 07h05 HE
|
Galena Biopharma, Inc.
GALE-301 is well-tolerated and elicits a strong and dose-dependent in vivo immune response; 1000 mcg identified as optimal dose
In the 1000 mcg vaccine dose group (VG), the clinical...
Galena Biopharma to Present GALE-301 Phase 2a Clinical Trial Data at the European Society for Medical Oncology (ESMO) European Cancer Congress 2015
14 sept. 2015 07h05 HE
|
Galena Biopharma, Inc.
PORTLAND, Ore., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
Galena Biopharma to Present at Two Upcoming Healthcare Investment Conferences
01 sept. 2015 07h05 HE
|
Galena Biopharma, Inc.
PORTLAND, Ore., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
Galena Biopharma Announces Independent Data Safety Monitoring Committee Recommends Reduction of Cardiac Toxicity Monitoring for NeuVax(TM) PRESENT Trial
24 août 2015 07h05 HE
|
Galena Biopharma, Inc.
PORTLAND, Ore., Aug. 24, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
Galena Biopharma Reports Second Quarter 2015 Financial Results
06 août 2015 16h10 HE
|
Galena Biopharma, Inc.
Completed over-enrollment in the NeuVax Phase 3 PRESENT breast cancer immunotherapy clinical trial and presented encouraging data for GALE-301 and GALE-401 programs
Achieved net revenue of...
Galena Biopharma Launches Zuplenz(R) (ondansetron) Oral Soluble Film
29 juil. 2015 07h05 HE
|
Galena Biopharma, Inc.
Zuplenz is indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting...
Galena Biopharma to Report Second Quarter Financial Results on Thursday, August 6, 2015
28 juil. 2015 07h05 HE
|
Galena Biopharma, Inc.
PORTLAND, Ore., July 28, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address...